PUBLISHER: The Business Research Company | PRODUCT CODE: 1957438
PUBLISHER: The Business Research Company | PRODUCT CODE: 1957438
Mid-sized pharmaceutical companies are defined as organizations with annual revenues ranging between $1 billion and $10 billion. These companies typically focus on areas such as drug development, niche market targeting, regional expansion, strategic partnerships, generic drug manufacturing, and contract manufacturing services.
The main approaches to drug development in mid-sized pharmaceutical companies include in-house development and outsourced development. In-house development refers to activities carried out internally by a company's own employees and departments rather than being delegated to external contractors. Within mid-sized pharmaceutical companies, in-house operations commonly include functions such as research and development, manufacturing, quality control, regulatory affairs, sales and marketing, and other core business activities. These companies operate both prescription and over-the-counter facilities that manufacture and sell medicines in forms such as tablets, capsules, injectables, sprays, and others, which are used to treat conditions including cardiovascular diseases, pain management, diabetes, cancer, and other disorders.
Tariffs have impacted the mid-size pharmaceuticals market by increasing the cost of imported raw materials, active pharmaceutical ingredients (APIs), and specialized manufacturing equipment. This has particularly affected contract manufacturing and generic drug production segments, especially in regions like Asia-Pacific and Europe that are major suppliers. While the tariffs have increased operational costs and slowed production timelines, they have also encouraged local sourcing, boosted domestic manufacturing investments, and accelerated innovation in cost-efficient drug development processes.
The mid-size pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides mid-size pharmaceuticals market statistics, including mid-size pharmaceuticals industry global market size, regional shares, competitors with a mid-size pharmaceuticals market share, detailed mid-size pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the mid-size pharmaceuticals industry. This mid-size pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The mid-size pharmaceuticals market size has grown strongly in recent years. It will grow from $760.71 billion in 2025 to $808.69 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increased r&d investments, expansion into emerging markets, adoption of generic drug production, growth of regional partnerships, rising prevalence of chronic diseases.
The mid-size pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $1059.05 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to advancements in personalized medicine, increased outsourcing of cros & cmos, adoption of ai-driven drug discovery, expansion of digital health platforms, growth in specialty pharmaceuticals. Major trends in the forecast period include niche drug development focus, regional market expansion, strategic partnerships & collaborations, generic drug manufacturing growth, contract manufacturing optimization.
The increasing prevalence of chronic diseases is expected to drive the growth of the mid-size pharmaceuticals market in the coming years. Chronic diseases, also referred to as non-communicable diseases, are long-term medical conditions that require continuous management and treatment, resulting in sustained demand for pharmaceutical products. Techniques such as mass spectrometry are widely used to identify, quantify, and analyze biomarkers and metabolites associated with chronic diseases, supporting drug development and disease management. As the burden of chronic illnesses continues to rise, it contributes directly to the expansion of the mid-size pharmaceuticals market. For instance, in June 2024, according to the National Health Service, 3,615,330 individuals registered with a general practitioner in the UK were diagnosed with non-diabetic hyperglycemia, or pre-diabetes, in 2023, representing an 18% increase compared to 3,065,825 cases in 2022. Therefore, the growing prevalence of chronic diseases is fueling the growth of the mid-size pharmaceuticals market.
Companies operating in the mid-size pharmaceuticals sector are increasingly concentrating on product development and new launches, including precision medicine platforms, to maintain and strengthen their market positions. A precision medicine platform is an advanced system designed to customize medical treatments based on individual patient characteristics, such as genetic profiles. For example, in February 2023, C4X Discovery Holdings PLC introduced its precision medicine platform, PatientSeek. The platform is intended to identify patient subgroups most likely to benefit from specific therapies based on genetic insights. The launch followed successful validation in patient stratification, where responsive patient groups were identified through retrospective analysis of a Phase 3 clinical trial in Parkinson's disease, highlighting the role of genetics in optimizing targeted treatment strategies.
In March 2023, Sun Pharmaceutical Industries Limited acquired Concert Pharmaceuticals Inc. for $576 million. Through this acquisition, Sun Pharmaceutical Industries gained full ownership of Concert's outstanding shares and added deuruxolitinib, a novel deuterated oral JAK1/2 inhibitor under development for the treatment of moderate to severe alopecia areata in adults, to its pipeline. Concert Pharmaceuticals Inc. is a US-based late-stage clinical mid-sized biopharmaceutical company focused on developing innovative medicines with distinct therapeutic profiles.
Major companies operating in the mid-size pharmaceuticals market are Baxter International Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Alexion Pharmaceuticals Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Eisai Co. Ltd., Les Laboratoires Servier S.A., Perrigo Co Plc, Aurobindo Pharma Limited., Cipla Limited, Hikma Pharmaceuticals, Endo International plc, Taisho Pharmaceutical Holdings Co. Ltd., BioMarin Pharmaceutical Inc., Mallinckrodt Plc, Exelixis Inc., Mylan Pharmaceuticals Inc., Neurocrine Biosciences Inc., Kyowa Kirin Co. Ltd., Emergent BioSolutions Inc.
North America was the largest region in the mid-size pharmaceutical market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mid-size pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the mid-size pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The mid-sized pharmaceuticals market consists of revenues earned by entities providing pharmaceutical services such as drug development, research activities, generic drug manufacturing, and contract manufacturing. The market value includes the value of related goods sold by the service provider or included within the service offering. The mid-sized pharmaceuticals market consists of the sales of goods such as prescription drugs, over-the-counter medications, generic drugs, and other pharmaceutical products targeting specific therapeutic areas or niche markets. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Mid-Size Pharmaceuticals Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses mid-size pharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for mid-size pharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mid-size pharmaceuticals market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.